patients with skeletal metastases due to breast cancer. *Pain* 2004;111: 306–12

13. Diel IJ et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. *Eur J Cancer* 2004;40:1704–12
14. Kohno N et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. *J Clin Oncol* 2005;23:3314–21
15. Wardley A et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised crossover study of community vs. hospital bisphosphonate administration. *Br J Cancer* 2005;92:1869–76
16. Lipton A et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. *Eur J Cancer* 2012;48:3082–92
17. Cleeland CS et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. *Cancer* 2013;119:832–8
18. Vadhan-Raj S et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. *Ann Oncol* 2012;23:3045–51
19. Martin M et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. *Clin Cancer Res* 2012;18:4841–9
20. Stopeck AT et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer* 2016;24: 447–55

Erratum

Erratum zum Beitrag: Vitamin C beim chronischen nicht spezifischen Kreuzschmerz

Olaf Buchbinder, Geldern; Geert-Jan van Geffen, Nijmegen/Niederlande; Hagen Maxeiner, Gießen; Gert Jan Scheffer, Nijmegen; Jörg Mühlhölzer, Nijmegen; *Schmerzmedizin* 2017;33(1):32–41
DOI: 10.1007/s00940-017-0495-6

Am Ende des Beitrags wurde der Name des Co-Autors Hagen Maxeiner falsch abgedruckt.

Die korrekten Autorenangaben lauten:

PD Dr. Hagen Maxeiner, D.E.S.A., E.D.I.C.

Universitätsklinikum Gießen und Marburg

Klinik für Anästhesiologie und Operative Intensivmedizin

Sektion Schmerztherapie

Gaffkystraße 14

35392 Gießen

Zitierweise:

Buchbinder et al. Vitamin C beim chronischen nicht spezifischen Kreuzschmerz. *Schmerzmedizin* 2017;33(2):25

DOI: 10.1007/s00940-017-0470-2

Hier steht eine Anzeige.